Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.

Svegliati-Baroni G, Pierantonelli I, Torquato P, Marinelli R, Ferreri C, Chatgilialoglu C, Bartolini D, Galli F.

Free Radic Biol Med. 2019 May 29. pii: S0891-5849(19)30326-0. doi: 10.1016/j.freeradbiomed.2019.05.029. [Epub ahead of print] Review.

PMID:
31152791
2.

The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study.

Vitale A, Farinati F, Pawlik TM, Frigo AC, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Cillo U.

Liver Int. 2019 Aug;39(8):1478-1489. doi: 10.1111/liv.14154. Epub 2019 Jun 26.

PMID:
31131974
3.

Brivanib in combination with Notch3 silencing shows potent activity in tumour models.

Giovannini C, Salzano AM, Baglioni M, Vitale M, Scaloni A, Zambrano N, Giannone FA, Vasuri F, D'Errico A, Svegliati Baroni G, Bolondi L, Gramantieri L.

Br J Cancer. 2019 Mar;120(6):601-611. doi: 10.1038/s41416-018-0375-4. Epub 2019 Feb 15.

PMID:
30765875
4.

Aging-Related Expression of Twinfilin-1 Regulates Cholangiocyte Biological Response to Injury.

Maroni L, Pinto C, Giordano DM, Saccomanno S, Banales JM, Spallacci D, Albertini MC, Orlando F, Provinciali M, Milkiewicz M, Melum E, Labiano I, Milkiewicz P, Rychlicki C, Trozzi L, Scarpelli M, Benedetti A, Svegliati Baroni G, Marzioni M.

Hepatology. 2018 Dec 18. doi: 10.1002/hep.30466. [Epub ahead of print]

PMID:
30561764
5.

Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.

Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G.

Transplantation. 2019 Jan;103(1):28-38. doi: 10.1097/TP.0000000000002483. Review.

PMID:
30300289
6.

Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.

Pierantonelli I, Svegliati-Baroni G.

Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480. Review.

PMID:
30300287
7.

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.

Vitale A, Farinati F, Noaro G, Burra P, Pawlik TM, Bucci L, Giannini EG, Faggiano C, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Fornari F, Marignani M, Vicari S, Bortolini E, Cozzolongo R, Grasso A, Aliberti C, Bernardi M, Frigo AC, Borzio M, Trevisani F, Cillo U; Italian Liver Cancer (ITA.LI.CA) group.

Hepatology. 2018 Oct;68(4):1232-1244. doi: 10.1002/hep.30185.

PMID:
30048016
8.

Correction: Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.

Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Am J Gastroenterol. 2018 Jul;113(7):1100. doi: 10.1038/s41395-018-0131-7.

PMID:
29910460
9.

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.

Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators.

Lancet. 2018 Jun 16;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7. Epub 2018 Jun 1. Erratum in: Lancet. 2018 Aug 4;392(10145):386.

PMID:
29861076
10.

Metabolic disorders across hepatocellular carcinoma in Italy.

Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2018 Nov;38(11):2028-2039. doi: 10.1111/liv.13877. Epub 2018 Jun 19.

PMID:
29745475
11.

Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group.

Vitale A, Lai Q, Farinati F, Bucci L, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Pawlik TM; Italian Liver Cancer (ITA.LI.CA) group.

J Gastrointest Surg. 2018 May;22(5):859-871. doi: 10.1007/s11605-018-3688-y. Epub 2018 Jan 19.

PMID:
29352441
12.

Author Correction: Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.

Pierantonelli I, Rychlicki C, Agostinelli L, Giordano DM, Gaggini M, Fraumene C, Saponaro C, Manghina V, Sartini L, Mingarelli E, Pinto C, Buzzigoli E, Trozzi L, Giordano A, Marzioni M, De Minicis S, Uzzau S, Cinti S, Gastaldelli A, Svegliati-Baroni G.

Sci Rep. 2017 Dec 11;7(1):17568. doi: 10.1038/s41598-017-17187-3.

13.

Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.

Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Hepatology. 2018 May;67(5):1784-1796. doi: 10.1002/hep.29668. Epub 2018 Apr 6.

PMID:
29159910
14.

Lipotoxicity and the gut-liver axis in NASH pathogenesis.

Marra F, Svegliati-Baroni G.

J Hepatol. 2018 Feb;68(2):280-295. doi: 10.1016/j.jhep.2017.11.014. Epub 2017 Nov 14. Review.

PMID:
29154964
15.

Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.

Pierantonelli I, Rychlicki C, Agostinelli L, Giordano DM, Gaggini M, Fraumene C, Saponaro C, Manghina V, Sartini L, Mingarelli E, Pinto C, Buzzigoli E, Trozzi L, Giordano A, Marzioni M, Minicis S, Uzzau S, Cinti S, Gastaldelli A, Svegliati-Baroni G.

Sci Rep. 2017 Sep 22;7(1):12200. doi: 10.1038/s41598-017-11744-6. Erratum in: Sci Rep. 2017 Dec 11;7(1):17568.

16.

Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of α-tocopherol (vitamin E).

Bartolini D, Torquato P, Barola C, Russo A, Rychlicki C, Giusepponi D, Bellezza G, Sidoni A, Galarini R, Svegliati-Baroni G, Galli F.

J Nutr Biochem. 2017 Sep;47:120-131. doi: 10.1016/j.jnutbio.2017.06.003. Epub 2017 Jun 7.

PMID:
28628909
17.

Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Valenti L, Svegliati-Baroni G, Ruscica M, Pipitone RM, Dongiovanni P, Rychlicki C, Ferri N, Cammà C, Fracanzani AL, Pierantonelli I, Di Marco V, Meroni M, Giordano D, Grimaudo S, Maggioni M, Cabibi D, Fargion S, Craxì A.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2660-2669. doi: 10.1210/jc.2017-00056.

PMID:
28472477
18.

Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.

Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Negrini G, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Mega A, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Craxì A, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) group.

J Hepatol. 2017 Jul;67(1):65-71. doi: 10.1016/j.jhep.2017.01.033. Epub 2017 Feb 10.

PMID:
28192185
19.

Pathophysiology of Non Alcoholic Fatty Liver Disease.

Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, Svegliati-Baroni G, Valenti L, Bonino F.

Int J Mol Sci. 2016 Dec 11;17(12). pii: E2082. Review.

20.

Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes.

Maroni L, Agostinelli L, Saccomanno S, Pinto C, Giordano DM, Rychlicki C, De Minicis S, Trozzi L, Banales JM, Melum E, Karlsen TH, Benedetti A, Baroni GS, Marzioni M.

Am J Pathol. 2017 Feb;187(2):366-376. doi: 10.1016/j.ajpath.2016.10.010. Epub 2016 Nov 30.

PMID:
27912077
21.

Natural history of nonalcoholic steatohepatitis-associated hepatocellular carcinoma.

Bellentani S, Baroni GS, Piscaglia F, Tiribelli C.

Clin Liver Dis (Hoboken). 2016 Oct 27;8(4):105-107. doi: 10.1002/cld.582. eCollection 2016 Oct. Review. No abstract available.

22.

Hepatitis E in a region of Italy: An emerging autochthonous infection?

Tarantino G, Bagnarelli P, Marzioni M, Marinelli K, Surace G, Traini S, Baroni GS, Menzo S, Benedetti A.

Dig Liver Dis. 2016 Nov;48(11):1340-1345. doi: 10.1016/j.dld.2016.06.035. Epub 2016 Jul 18.

PMID:
27476463
23.

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F; Italian LiverCancer (ITA.LI.CA) group.

Liver Int. 2017 Mar;37(3):423-433. doi: 10.1111/liv.13242. Epub 2016 Oct 2.

PMID:
27566596
24.

The evolutionary scenario of hepatocellular carcinoma in Italy: an update.

Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2017 Feb;37(2):259-270. doi: 10.1111/liv.13204. Epub 2016 Aug 17.

PMID:
27427866
25.

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.

Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group.

PLoS Med. 2016 Apr 26;13(4):e1002006. doi: 10.1371/journal.pmed.1002006. eCollection 2016 Apr.

26.

Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.

Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group.

Am J Gastroenterol. 2016 Jan;111(1):70-7. doi: 10.1038/ajg.2015.389. Epub 2016 Jan 5. Erratum in: Am J Gastroenterol. 2018 Jul;113(7):1100.

PMID:
26729544
27.

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study.

Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group.

Hepatology. 2016 Mar;63(3):827-38. doi: 10.1002/hep.28368. Epub 2016 Jan 14.

PMID:
26599351
28.

LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.

Ceccarelli S, Panera N, Mina M, Gnani D, De Stefanis C, Crudele A, Rychlicki C, Petrini S, Bruscalupi G, Agostinelli L, Stronati L, Cucchiara S, Musso G, Furlanello C, Svegliati-Baroni G, Nobili V, Alisi A.

Oncotarget. 2015 Dec 8;6(39):41434-52. doi: 10.18632/oncotarget.5163.

29.

Prevalence and clinical outcome of hepatic haemangioma with specific reference to the risk of rupture: A large retrospective cross-sectional study.

Mocchegiani F, Vincenzi P, Coletta M, Agostini A, Marzioni M, Baroni GS, Giovagnoni A, Guerrieri M, Marmorale C, Risaliti A, Vivarelli M.

Dig Liver Dis. 2016 Mar;48(3):309-14. doi: 10.1016/j.dld.2015.09.016. Epub 2015 Oct 3.

PMID:
26514738
30.

Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.

Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato G, Cillo U; Italian Liver Cancer Group.

Liver Transpl. 2015 Oct;21(10):1250-8. doi: 10.1002/lt.24214.

31.

Immunological risk factors in biliary strictures after liver transplantation.

Mocchegiani F, Vincenzi P, Lanari J, Montalti R, Nicolini D, Svegliati Baroni G, Risaliti A, Vivarelli M.

Ann Transplant. 2015 Apr 20;20:218-24. doi: 10.12659/AOT.892393.

32.

Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.

Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Baroni GS, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, Lucà MG, Russo FP, Cillo U, Fagiuoli S; Liver Transplantation NITp working group.

Transpl Int. 2015 Sep;28(9):1055-65. doi: 10.1111/tri.12591. Epub 2015 Apr 30.

33.

PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: perspectives in the diagnosis of pancreatic cancer.

Marzioni M, Germani U, Agostinelli L, Bedogni G, Saccomanno S, Marini F, Bellentani S, Barbera C, De Minicis S, Rychlicki C, Santinelli A, Ferretti M, Di Maira PV, Baroni GS, Benedetti A, Caletti G, Lorenzini I, Fusaroli P.

Dig Liver Dis. 2015 Feb;47(2):138-43. doi: 10.1016/j.dld.2014.10.010. Epub 2014 Nov 8.

PMID:
25454709
34.

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study.

Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U; Italian Liver Cancer (ITA.LI.CA) group.

J Hepatol. 2015 Mar;62(3):617-24. doi: 10.1016/j.jhep.2014.10.037. Epub 2014 Oct 30.

PMID:
25450706
35.
36.

Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.

Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M.

PLoS One. 2014 Oct 23;9(10):e110284. doi: 10.1371/journal.pone.0110284. eCollection 2014.

37.

Liver transplantation in patients with common variable immunodeficiency: a report of two cases.

Montalti R, Mocchegiani F, Vincenzi P, Svegliati Baroni G, Nicolini D, Vivarelli M.

Ann Transplant. 2014 Oct 23;19:541-4. doi: 10.12659/AOT.890952.

38.

Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury.

Marzioni M, Agostinelli L, Candelaresi C, Saccomanno S, De Minicis S, Maroni L, Mingarelli E, Rychlicki C, Trozzi L, Banales JM, Benedetti A, Baroni GS.

Hepatology. 2014 Oct;60(4):1324-35. doi: 10.1002/hep.27262. Epub 2014 Aug 25.

PMID:
24925797
39.

HCC development is associated to peripheral insulin resistance in a mouse model of NASH.

De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, Candelaresi C, Giaccari A, Trozzi L, Pierantonelli I, Mingarelli E, Marzioni M, Muscogiuri G, Gaggini M, Benedetti A, Gastaldelli A, Guido M, Svegliati-Baroni G.

PLoS One. 2014 May 22;9(5):e97136. doi: 10.1371/journal.pone.0097136. eCollection 2014.

40.

Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.

Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Cancer. 2014 Jul 15;120(14):2150-7. doi: 10.1002/cncr.28706. Epub 2014 Apr 10.

41.

Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.

Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Giannini EG, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD; Italian Liver Cancer Group.

J Hepatol. 2014 Aug;61(2):333-41. doi: 10.1016/j.jhep.2014.03.037. Epub 2014 Apr 6.

PMID:
24717522
42.

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.

Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C, D'Anzeo M, Benedetti A, Cascinu S.

BMC Cancer. 2014 Feb 20;14:110. doi: 10.1186/1471-2407-14-110.

43.

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.

Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, Toniutto P, Fava G, De Minicis S, Mandolesi A, Bianconi M, Giampieri R, Granito A, Facchetti F, Bitetto D, Marinelli S, Venerandi L, Vavassori S, Gemini S, D'Errico A, Colombo M, Bolondi L, Bearzi I, Benedetti A, Cascinu S.

Int J Cancer. 2014 Sep 1;135(5):1247-56. doi: 10.1002/ijc.28772. Epub 2014 Feb 20.

44.

The impact of translational research on gastroenterology.

Di Sabatino A, Moschetta A, Conte D, Tiribelli C; Translational Committee of the Italian Society of Gastroenterology, Caprioli FA, Fabris L, Fantini MC, Frulloni L, Monteleone G, Romano M, Sarnelli G, Baroni GS.

Dig Liver Dis. 2014 Apr;46(4):293-4. doi: 10.1016/j.dld.2013.12.015. Epub 2014 Feb 5. No abstract available.

PMID:
24508099
45.

Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.

Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M.

World J Gastroenterol. 2013 Sep 14;19(34):5622-32. doi: 10.3748/wjg.v19.i34.5622.

46.

Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice.

De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G.

Hepatology. 2014 May;59(5):1738-49. doi: 10.1002/hep.26695. Epub 2014 Feb 25.

PMID:
23959503
47.

Semaphorin 7A contributes to TGF-β-mediated liver fibrogenesis.

De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Trozzi L, Candelaresi C, Bataller R, Millán C, Brenner DA, Vivarelli M, Mocchegiani F, Marzioni M, Benedetti A, Svegliati-Baroni G.

Am J Pathol. 2013 Sep;183(3):820-30. doi: 10.1016/j.ajpath.2013.05.030. Epub 2013 Jul 11.

48.

New insights in hepatocellular carcinoma: from bench to bedside.

De Minicis S, Marzioni M, Benedetti A, Svegliati-Baroni G.

Ann Transl Med. 2013 Jul;1(2):15. doi: 10.3978/j.issn.2305-5839.2013.01.06. Review.

49.

Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres.

Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Poggio PD, Rapaccini G, Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Baroni GS, Morisco F, Pecorelli A, Farinati F; Italian Liver Cancer (ITA.LI.CA) Group.

Liver Int. 2013 Oct;33(9):1420-7. doi: 10.1111/liv.12208. Epub 2013 Jun 12.

PMID:
23758775
50.

From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights.

De Minicis S, Day C, Svegliati-Baroni G.

Curr Pharm Des. 2013;19(29):5239-49. Review.

PMID:
23394093

Supplemental Content

Loading ...
Support Center